Lv3
380 积分 2025-10-30 加入
Synthesis, preclinical, and initial clinical evaluation of integrin αVβ3 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [68Ga]Ga-RGD-RM26-03
17天前
已完结
Cumulative Absorbed Dose and Successive Cyclic Reduction in Absorbed Dose Predict Response to 177Lu-DOTATATE in Neuroendocrine Tumors
17天前
已完结
The additive value of 68Ga-RM26 PET/CT to 68Ga-PSMA−617 PET/CT in assessing Post-treatment outcomes of ARSIs in mCRPC patients
1个月前
已完结
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
1个月前
已完结
Prompt PSA changes as a prognostic marker for response to PSMA-radioligand therapy
1个月前
已完结
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
1个月前
已完结
Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes
1个月前
已完结
Heterogeneity of [68Ga]Ga-PSMA-11 PET/CT in metastatic castration-resistant prostate cancer: genomic characteristics and association with abiraterone response
1个月前
已完结
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial
1个月前
已完结
Value of [68Ga]Ga-PSMA-11 PET/CT in Reflecting the Intra- and Intertumor Heterogeneity of Neovascularization in Clear Cell Renal Cell Carcinoma
1个月前
已完结
皖公网安备34019202002308
